Skip to content

Effectiveness of Superior Hypogastric Plexus chemical ablation for Chronic pelvic pain in pelvic cancers

Effectiveness of Superior Hypogastric Plexus Neurolysis for Chronic pelvic pain in pelvic malignancies - A Randomized Controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/077417
Enrollment
40
Registered
2024-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Superior Hypogastric Plexus neurolysis on chronic pelvic pain in pelvic malignancy on pain and quality of life: The patient will be positioned prone. Under sterile precautions, under f

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with Chronic pelvic pain due to any type of pelvic malignancies 2. Patients with no symptomatic relief taking Tab 50 mg of Morphine(10 mg Q4H)

Exclusion criteria

Exclusion criteria: 1.Spinal cord deformities 2.History of spine surgery 3.Increased vascularity along needle pathway from CT scan 4.History of allergy to local anesthetics 5.Not able to lie in prone position 6.Bleeding disorders 7.Psychiatric disorders 8.Pregnancy/Lactation

Design outcomes

Primary

MeasureTime frame
Patients with pelvic malignancies receiving block and Conventional oral Analgesia are compared on pain relief based on VAS Score from 0-10 cmTimepoint: All patients will be evaluated for the reduction in the VAS score weekly for first month,then biweekly for the 2nd month then once in the last month through telephonic follow-up

Secondary

MeasureTime frame
Patients with pelvic malignancies receiving block and Conventional oral Analgesia are compared based on 1.European Pain Federation Score(Quality of life) 2.Adverse effects Timepoint: European pain Federation Score,Adverse effects will be evaluated weekly for the first month,biweekly for the 2nd month then once in last month through telephonic communication.

Countries

India

Contacts

Public ContactDr PRITHIKSHA S

JIPMER

dr.lenin@gmail.com9487981140

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026